Clinical and Biological Features of Response in Resistant Neuroblastoma to <sup>131</sup> I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era
BACKGROUND: I-MIBG in the anti-GD2 era are unknown, and the factors associated with response are poorly defined. PROCEDURE: I-MIBG and evaluated the association between clinical and molecular features-including receipt of anti-GD2 immunotherapy-and ORR among participants with R/R NB from 2011 to 2023. Variables with an unadjusted odds ratio [uOR] p < 0.2 in a univariable screen were included in multivariable analysis. RESULTS: I-MIBG. Asians compared to Whites (adjusted OR 0.21 [0.05-0.95]), no bone marrow disease (0.17 [0.06-0.50]), and higher Curie score (0.90 [0.83-0.98]) were significantly associated with lower odds of response. CONCLUSION: I-MIBG therapy.
Authors
- Fabienne Hollinger
- Katherine K. Matthay (ORCID: https://orcid.org/0000-0002-0146-2499)
- Ann Lazar (ORCID: https://orcid.org/0000-0002-6341-0360)
- Kieuhoa T. Vo
- Steven G. DuBois (ORCID: https://orcid.org/0000-0003-0882-738X)
- Catriona Black
- Benjamin J. Lerman (ORCID: https://orcid.org/0000-0001-9973-6779)
- Miguel Pampaloni
Institutions
- University of California, San Francisco (US)
- UCSF Benioff Children's Hospital (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1002/1545-5017.70385
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00